Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a study that compared intraocular inflammatory events and side effects in patients treated with aflibercept 2 mg, aflibercept ...

The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA ® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Eight weeks after the loading phase with 8 mg ...

P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...

Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss. Early ...

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor first approved for treatment of diabetic macular edema (DME) in July 2014 after several large trials showed it was superior to ...

As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a motion seeking to establish a multi-district litigation (“MDL”) encompassing the aflibercept BPCIA ...

Pune, India - (NewMediaWire) - March 7, 2023 - "Aflibercept" Size, Scope, and Forecast 2023-2031 report has been added to the Market Research Archive of Absolute Reports. Industry experts and ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of aflibercept, having considered evidence on the nature of diabetic macular oedema (DMO) and the value ...